First Bank & Trust Takes $1.22 Million Position in GSK PLC Sponsored ADR $GSK

Key Points

• First Bank & Trust has acquired a new position in GSK PLC Sponsored ADR, purchasing 31,667 shares valued at approximately $1.22 million in the second quarter of 2023.
• GSK reported a Q2 earnings per share (EPS) of $1.23, surpassing estimates, and had revenue of $10.64 billion, significantly exceeding expectations.
• The company announced a $0.4206 quarterly dividend with a yield of 4.2%, but also cut its dividend payout ratio to 77.78%.

First Bank & Trust bought a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 31,667 shares of the pharmaceutical company's stock, valued at approximately $1,216,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its stake in GSK by 222.2% in the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of GSK in the 1st quarter valued at about $31,000. Richardson Financial Services Inc. lifted its stake in GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares during the last quarter. Olde Wealth Management LLC acquired a new stake in GSK in the 1st quarter valued at about $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its holdings in GSK by 525.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after purchasing an additional 852 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK stock opened at $40.31 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The company has a market cap of $82.10 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 2.04 and a beta of 0.53. The company has a 50 day moving average of $38.78 and a 200-day moving average of $38.49. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $43.62.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company's revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's dividend payout ratio (DPR) is 77.78%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Berenberg Bank restated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Reduce" and an average price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.